Thursday 5 March, 2009

Levocetirizine (Xyzal): Synthon announced EU approval

Synthon announced today that it has successfully concluded its registration procedures for Levocetirizine. Regulatory clearance has been obtained for Synthon's product in around fourteen European countries using decentralized procedures (DCP). Registration has been established for 5 mg filmcoated tablets. Synthon's product is a fully bioequivalent version of the oral anti-histamine drug Xyzal®. The product contains the active ingredient levocetirizine, which is the enantiopure form of cetirizine, the active ingredient in UCB’s product Zyrtec®.
(Source pharmalive Here)

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker